Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neonatal antithrombin III deficiency.

M J Manco-Johnson1

  • 1Department of Pediatrics, University of Colorado Health Sciences Center, Denver 80262.

The American Journal of Medicine
|September 11, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Effect of late prophylaxis in hemophilia on joint status: a randomized trial.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2015
Same author

Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study.

Journal of thrombosis and haemostasis : JTH·2015
Same journal

GLP-1 Receptor Agonists and Age-related Macular Degeneration Risk in Diabetes or Non-diabetic Obesity: A Retrospective Cohort Study.

The American journal of medicine·2026
Same journal

Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

The American journal of medicine·2026
Same journal

Cave Canem - Beware of the Dog.

The American journal of medicine·2026
Same journal

Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

The American journal of medicine·2026
Same journal

Mesenteric Panniculitis.

The American journal of medicine·2026
Same journal

Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

The American journal of medicine·2026
See all related articles

Sick preterm infants often experience bleeding and clotting issues due to low antithrombin III (ATIII) levels. Lower ATIII levels correlate with worse outcomes, suggesting ATIII replacement therapy may benefit these infants.

Area of Science:

  • Neonatal Medicine
  • Hematology
  • Pediatric Critical Care

Background:

  • Hemorrhagic and thrombotic complications are frequent in sick preterm infants, indicating potential coagulation dysregulation.
  • Neonates naturally have lower antithrombin III (ATIII) levels than adults, which are further reduced in preterm infants with critical illnesses.
  • Low cord blood ATIII levels in neonates are associated with adverse outcomes, including increased mortality and incidences of intracranial hemorrhage and catheter-related thrombosis.

Purpose of the Study:

  • To investigate the role of antithrombin III (ATIII) in coagulation regulation in sick preterm infants.
  • To explore the association between ATIII levels and clinical outcomes in this population.
  • To establish the rationale for potential ATIII replacement therapy in preterm infants with ATIII deficiency.

Related Experiment Videos

Main Methods:

  • Review of existing clinical data and trials concerning coagulation complications in preterm infants.
  • Analysis of the correlation between ATIII levels (measured in cord blood and plasma) and clinical outcomes.
  • Evaluation of the efficacy of plasma replacement and anticoagulation therapies in high-risk infants.

Main Results:

  • Sick preterm infants, particularly those with respiratory distress, necrotizing enterocolitis, sepsis, or disseminated intravascular coagulation, exhibit very low plasma ATIII levels.
  • Lower ATIII levels at birth are linked to poorer outcomes, including higher mortality and increased risk of intracranial hemorrhages and catheter-related thromboses.
  • Clinical trials indicate that plasma replacement and anticoagulation therapies can mitigate hemorrhagic and thrombotic complications in high-risk infants.

Conclusions:

  • Severe ATIII deficiency is a significant concern in sick preterm infants, contributing to adverse hemorrhagic and thrombotic events.
  • The findings support the hypothesis that ATIII plays a critical role in maintaining hemostasis in neonates.
  • These data provide a strong rationale for considering antithrombin III (ATIII) replacement therapy in preterm infants with documented ATIII deficiency to improve outcomes.